A 42-year-old female with schizoaffective disorder has been on quetiapine 600 mg daily for 18 months with good psychiatric symptom control. At her routine metabolic monitoring visit, her fasting glucose is 118 mg/dL, up from 96 mg/dL at baseline. Hemoglobin A1c is 6.1%, up from 5.4%. Her BMI has increased from 28 to 33 over the treatment period. She reports increased thirst and urinary frequency over the past two months. Family history is significant for type 2 diabetes in her mother and maternal grandmother. Her fasting lipid panel shows triglycerides of 224 mg/dL and HDL of 38 mg/dL. The PMHNP is evaluating the metabolic findings and their implications for ongoing treatment. Which of the following best represents the appropriate evaluation?